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A Proposal for the Clinical Use of Flecainide 
JEFFREY L. ANDERSON, MD, JAMES R. STEWART, MD, and BARRY J. CREVEY, MD 
Effective antiarrhythmic therapy requires a carefully 
considered approach, including an understanding 
of the arrhythmia, the underlying cardiac disease 
and the drug’s pharmacokinetics. Flecainide is a 
new antiarrhythmic drug that may soon be released 
for general use. Flecainide demonstrates unsur- 
passed efficacy in chronic ventricular arrhythmias 
in stable patients and may become a first-choice 
drug because of its ease of administration, efficacy 
and favorable tolerance. Twice-daily dosing with 
100 to 200 mg usually provides effective therapy. 
Clinical experience suggests flecainide to be indi- 
cated in the treatment of uniform and multiform 
ventricular premature complexes, coupled ven- 
tricular premature complexes, and episodes of 
nonsustained ventricular tachycardia. A lower re- 
sponse rate is observed in preventing induction of 
sustained ventricular tachycardia, and these pa- 
tients should be carefully selected. Flecainide is 
promising in the treatment of supraventricular 
tachycardias using atrioventricular nodal or extra- 
nodal reentrant pathways, although this use is still 
investigational in the United States. The drug’s use 
for arrhythmias during acute myocardial infarction 
requires further study. Flecainide possesses modest 
negative inotropic potential. Proarrhythmic or other 
adverse reactions have occurred primarily in set- 
tings of high drug level, poor ventricular function 
or refractory, malignant arrhythmias, suggesting 
caution in these groups. 
(Am J Cardiol 1984;53:1128-1198) 
Effective therapy of cardiac arrhythmias requires a 
carefully considered approach.’ The first step in ar- 
rhythmia management is an accurate cardiac diagnosis, 
which includes documentation and identification of the 
arrhythmia and evaluation of underlying heart disease. 
Specific initiating factors should be identified. Elec- 
trolyte, acid base and other metabolic derangements, 
neuroendocrine factors or adverse drug interactions 
should be addressed. Antiarrhythmic goals should be 
specified in advance and may include elimination of 
symptoms (palpitation), suppression of ectopic ven- 
tricular complexes, elimination of repetitive complexes 
or prevention of ventricular tachycardia and fibrillation. 
Drug administration should be based on sound clinical 
and pharmacologic principles. Disease states may alter 
drug effects and disposition. Once therapy has begun, 
careful follow-up should be undertaken, including 
documentation of antiarrhythmic effects, observation 
for adverse effects and, when appropriate, drug plasma 
concentration. 
In association with organic heart disease, particularly 
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coronary artery disease, complex ventricular arrhyth- 
mias may be associated with an increased risk of mor- 
tality, particularly from sudden death due to ventricular 
fibrillation.2p3 Studies documenting the ability of anti- 
arrhythmic therapy to reduce this excessive risk are 
incomplete. However, a carefully applied approach 
appears to hold promise.4 Therapy for ventricular ar- 
rhythmias is indicated in the following settings: (1) 
primary ventricular fibrillation unprovoked by myo- 
cardial infarction; (2) complex ventricular arrhythmias 
(pairs, runs, R-on-T complexes and high frequency ar- 
rhythmia) after myocardial infarction, particularly 
during the first year; (3) complex arrhythmias in asso- 
ciation with ischemia; (4) ventricular tachycardia, 
particularly in coronary artery disease; (5) syncope as- 
cribed to ventricular tachycardia of any origin; (6) ar- 
rhythmias causing significant clinical symptoms (pal- 
pitation, dyspnea, fatigue and dizziness).315 
An ideal antiarrhythmic drug should possess a high 
degree of effectiveness, a low level of toxicity with a wide 
therapeutic range and prolonged antiarrhythmic ac- 
tion.6 The clinical management of ventricular ar- 
rhythmias remains problematic, however, because of the 
frequent failure of standard drugs which may be at- 
tributable to inadequate antiarrhythmic activity, in- 
tolerable adverse effects or compliance problems. In this 
regard, flecainide acetate possesses several favorable 
properties compared with available antiarrhythmic 
agents: excellent ant&rhythmic potency per milligram, 
effectiveness against ventricular arrhythmias in a high 
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percentage of patients, a low incidence of major adverse 
effects, and a long half-life, which favors patient com- 
pliance and continuous antiarrhythmic action.7 
We are presenting a long-term patient experience, 
reviewing important investigative observations (many 
detailed in this symposium), and formulating guidelines 
for the initial clinical application of flecainide. 
Application of Clinical Pharmacology 
Only by applying a thorough understanding of a 
drug’s unique pharmacologic characteristics can max- 
imal therapeutic benefit be realized (Table I). 
Metabolism in humans? After oral administration, 
the absorption of flecainide is nearly complete, and 
presystemic (first-pass) metabolism is negligible, re- 
sulting in systemic bioavailability of more than 90%. 
Peak plasma drug levels occur at about 3 hours (range 
1 to 6). Food does not deter the rate or extent of fle- 
cainide absorption. Increases in oral dosage lead to in- 
creases in plasma level in a linear fashion. 
The mean plasma elimination half-life in patients 
with ventricular arrhythmias as determined in several 
studies averages about 20 hours (range 12 to 27).7,gJo 
This result is somewhat longer than the 14-hour mean 
half-life noted after single oral doses given to healthy 
persons.” Minimum therapeutic plasma concentrations 
associated with greater than 90% suppression of ven- 
tricular premature complexes (VPCs) in responding 
patients range from 200 to 1,000 ng/ml (mean 500). In 
patients with advanced cardiac disease, major adverse 
cardiac effects have usually occurred in association with 
plasma levels greater than 1,000 to 1,500 ng/ml. Because 
antiarrhythmic effects are related to parent drug, 
plasma determinations of flecainide may provide useful 
clinical information. Elimination of flecainide is pri- 
marily renal, consisting of unchanged drug and 2 major 
urinary metabolites with little or no antiarrhythmic 
activity. Plasma protein binding is low (about 40%) and 
independent of plasma drug levels. Drug interactions 
of consequence have not been observed. Despite the 
high percentage of flecainide circulating as free drug, 
its large volume of distribution (about 10 liters/kg) 
precludes effective removal of flecainide by hemo- 
dialysis. 
Urinary excretion in moderate renal failure is only 
somewhat less than that in healthy subjects; in contrast, 
urinary elimination may be markedly lower with end- 
stage renal disease. Observation suggests a decrease of 
about 25% in the rate of flecainide elimination from 
plasma in patients with congestive heart failure (New 
York Heart Association class III or IV). Drug interac- 
tions with flecainide appear to be minor. The addition 
of flecainide in subjects receiving maintenance digoxin 
results in about a 15% increase in digoxin concentration, 
an insignificant change. Concurrent administration of 
flecainide and propranolol results in plasma increases 
in flecainide averaging 20% and propranoiol of 30% in 
healthy subjects. Therefore, the pharmacokinetic profile 
of flecainide is favorable in many regards, and major 
anomalies of clinical significance have not been de- 
scribed. 
Electrophysiologic implications: Flecainide 
TABLE I Clinical Pharmacoloav of Oral Flecainide 
Bioavailability: >90% 
Minimum effective plasma concentration range: 200 to 1,000 
ng/ml (mean 506) 
Elimination half-life: 20 hours (range 12 to 27) 
Elimination: Renal 
Plasma protein binding: 40 % 
Active metabolites: None of significance 
belongs to the membrane-stabilizing (class I) group of 
antiarrhythmic agents; however, it has its own charac- 
teristic electrophysiologic profile.12J” In humans, fle- 
cainide depresses conduction in all parts of the heart, 
with greatest effects on the His-Purkinje system. Effects 
on refractory periods are less pronounced and primarily 
limited to the ventricle.‘” Sinus node recovery times are 
usually unaffected except in certain patients with sick 
sinus syndrome, in whom flecainide occasionally may 
result in pronounced lengthening.14 Prolongation of PR 
and QRS intervals is greater during treatment with 
flecainide than with standard drugs?J5J6 but effects 
on the QT interval are small15 (Table II). Increases in 
PR and QRS intervals of about 20% commonly occur at 
doses of 400 mg/day, and are usually not a cause for 
concern.7J3J5 Those with initially increased PR and 
QRS intervals are not disproportionately affected.‘” 
Similar electrocardiographic changes also are noted with 
encainide.17p18 Clinically, an increase in electrocardio- 
graphic intervals of more than 50%, substantial in- 
creases in corrected QT intervallg or the development 
of new bundle branch block should raise a clinical con- 
cern, particularly in patients with advanced disease. The 
development of bifascicular block or second-degree or 
greater heart block is an indication for drug reduction 
or discontinuation unless a pacemaker is present to 
sustain rhythm. 
Hemodynamic considerations: Flecainide has been 
well tolerated hemodynamically. Blood pressure is 
typically unchanged. Small increases have occasionally 
been noted, and rarely increases in antihypertensive 
therapy are needed. Heart rate is unchanged, although 
rarely bradycardia or tachycardia may be seen. Among 
antiarrhythmic drugs, flecainide appears to have in- 
termediate negative inotropic potential. In stable pa- 
TABLE II Cardiovascular Effects of Oral Flecainide 
Blood pressure: - (*t) 
Heart rate: - 
Electrocardiogra hit intervals’: 
APR: 0.04 s ( f 23%), p <O.Ol 
AQRS: 0.02 s (720%). p <O.OI 
AQT: 0.03 s (t7%). p co.05 
&T+: 0.01 s (t4%), p = NS 
Worsening heart failure: 
Overall: 2.1% (8/373) 
Previous failure: 9.0% (6/67) 
Proarrhythmic effect: treatment groups 
Chronic stable arrhythmias: 4% 
Unstable arrhythmia patients: 12 % 
Overall: 7.5 % (44/588) 
l During doses of 400 to 600 mg/day.15 
+ AJT = AQT - AQRS; a measure of independent effects on 
QT.‘,‘5 
NS = not significant. 
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TABLE III Efficacy of Oral Flecainide 
Summary of Representative Trials 
% Responders % VPC Suppression % Suppression Mean Dose (mg/day) 
Study (n) (>80% VPC Suppression) (Mean Frequency Reduction) Couplets, Runs (Range) 
Multicenter 97% >99% 400 
dose ranging (n = 33)‘1~-‘~ 
97 (32/33) 
Flecainide-quinidine 85 95 % , mean 100% reduction in 75% (20:~0600) 
comparison (n = 233)15 80% reduction in 90% 
Flecainide, mexiletine, 82 (9/l 1) 
(99G;$+median) 
. 0 98.8% (40:oo600) 
propafenone 
comparison (n = 12)22 
VPC = ventricular premature complexes. 
tients, electrocardiographic ejection fraction does not 
change during maintenance therapy.7sgJ0 Twelve pa- 
tients with compromised left ventricular function were 
studied by radionuclide ventriculography before and 
during maintenance therapy: ejection fraction averaged 
42% before and 38% after therapy; this decrease was not 
associated with clinical failure.20 In a retrospective 
analysis of 373 patients treated with flecainide, in 4.3% 
(16 patients), signs or symptoms developed that might 
be indicative of heart failure, possibly related to fle- 
cainide therapy. In a subgroup with previous heart 
failure, symptoms developed in 15% (10 of 6’7). However, 
a closer examination of each patient’s clinical history 
indicated that only 2.1% (8 patients) and 9% (6 of 67), 
respectively, had evidence of heart failure possibly at- 
tributable to flecainide therapy. These figures suggest 
that flecainide is better tolerated hemodynamically 
than disopyramide21 or propafenone.22 In conclusion, 
flecainide may be used without concern in those with 
normal or moderately depressed left ventricular func- 
tion, but caution should be used in those with more 
advanced dysfunction with preexistent heart failure. 
Review of Clinical Experience and Use 
Clinical studies: Flecainide has been administered 
to approximately 1,000 American patients during clin- 
ical investigative studies (Table III). European expe- 
rience is broader; flecainide has rapidly achieved a 
position among the most commonly prescribed antiar- 
rhythmic drugs in areas where it is now generally 
available. 
Clinical efficacy of the oral drug was initially dem- 
onstrated in the United States in a 3-center dose-finding 
and short-term efficacy tria1.7pgJ0 Flecainide therapy 
resulted in suppression of ventricular premature com- 
plexes averaging 97% in the 33 patients studied. The 
average dose was 400 mg/day. Repetitive ventricular 
activity was essentially eliminated. 
More recently, the efficacy of flecainide (200 to 300 
mg b.i.d.) has been compared with that of quinidine (300 
to 400 mg q.i.d.) in a large multicenter trial.l5 Both 
drugs were effective in arrhythmia suppression, but the 
response to flecainide was substantially greater, re- 
sulting in 95% VPC suppression, vs 70% during quini- 
dine. Seventy-five percent of patients achieved more 
than 95% suppression with flecainide, as opposed to 35% 
in the parallel group treated with quinidine (p <O.OOl). 
Couplets were eliminated in 70% of patients treated 
with flecainide; quinidine eliminated the couplets in 
only 41% (p <O.OOl). Similarly, ventricular runs were 
eliminated in 80% treated with flecainide, vs 55% with 
quinidine. 
In another clinical trial, the antiarrhythmic efficacy 
of flecainide was compared with that of mexiletine, a 
lidocaine congener, and propafenone, another potent 
type I agent. 22 Response to flecainide was superior in 
terms of efficacy and tolerance. Arrhythmia (VPC) re- 
duction averaged 94% after flecainide (400 mg/day), 80% 
after propafenone (900 mglday) and only 53% after 
mexiletine (600 mg/day) in 12 patients with coronary 
artery disease. Repetitive extrasystoles were reduced 
by 99,97 and 83% by the 3 drugs, respectively, in this 
blinded, crossover study. Side effects led to discontin- 
uation of propafenone and mexiletine in 2 patients 
each. 
Experience has been more limited in patients with 
inducible ventricular tachycardia by programmed 
electrical stimulation.i3 In 15 consecutive patients 
studied in our laboratory, oral flecainide prevented 
tachycardia induction in 9 (60%) and improved the re- 
sponse in 2 others, a 73% overall favorable response. 
Higher response rates have not been reported for other 
class I agents. However, response in these patients is 
evidently less than that in stable patients without 
ventricular tachycardia and depends on patient selec- 
tion and stimulation protoco1.23l24 
Long-Term Experience in 
Treating Complex Arrhythmias 
Antiarrhythmic experience extending over several 
years is important in assessing clinical safety and effi- 
cacy. Such experience with flecainide is still limited and 
will require further observation. Our own experience 
with a small group of patients presenting initially with 
complex ventricular arrhythmias follows. 
Ten consecutive patients entered into long-term 
flecainide therapy on the basis of an initial successful 
response (80% suppression) (Table IV).7925 At the end 
of a short-term study (14 days), geometric mean VPC 
frequency had been reduced by 99.5% (p <O.OOl) (Table 
V). The effective drug dose averaged 420 mg/day (range 
300 to 600), given in divided doses every 12 hours. Me- 
dian plasma flecainide concentration was 837 ng/ml 
(range 357 to 1,615) (Table V). Patients were continued 
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TABLE IV Experience with Long-Term Therapy 
No. of 
Age (yr) Arrhythmia Previous Follow-Up 
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Failure (exercise VT) 
Failure (exercise VT) 
Successful (X21 mo); 
late failure (VT) 
Successful 
Successful 
* Includes disopyramide (5 patients), lidocaine (1 patient), phenytoin (2 patients), procainamide (6 patients), propranolol (6 patients), quinidine 
(8 patients) and tocainide (1 patient). 
AS = aortic stenosis; ASD = atrial septal defect; AVD = aortic valve disease (biscuspid); CAD = coronary artery disease; CM = cardiomyopathy; 
Ml = myocardial infarction; MR = mitral regurgitation; MVP = mitral valve prolapse. 
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16 921 1,160 
0 544 892 ‘$63 
74 1,291 1,589 1,444 
357 1,284 1,476 
777 967 727 
1,615 
743 1:421 ::: 
897 1,047 
... ... 1,012 ... 
... ... 845 
l After attempted dosage reduction. 
r Sustained ventricular tachycardia, 136 beats/min 
t Predose (trough). 
* Random. 
on the same dose of medication and were followed 
monthly for 4 months and bimonthly thereafter. His- 
tory, examination, la-lead electrocardiography with 
l-minute rhythm strip and blood chemistry tests were 
performed at each visit and 24-hour ambulatory (Hol- 
ter) electrocardiographic recordings at 4-month inter- 
vals. 
The follow-up period ranged from 3 months in a pa- 
tient with early treatment failure to 37 months, with a 
median of 25 months (Tables IV and V). In the 9 pa- 
tients successfully treated at 6 months, geometric mean 
VPC frequency was 8.0/hour (range 0 to 258), repre- 
senting 99% suppression with respect to baseline. An 
additional treatment failure occurred between 6 and 12 
months, and 1 each during the second and third treat- 
ment years. During successful treatment at 18 to 36 
months (n = 7), geometric mean VPC frequency was 
6.2/hour (range 0 to 781, representing 99.6% continued 
VPC suppression. 
Treatment failures included ventricular tachycardia 
in 3 instances and supraventricular arrhythmia in 1. In 
Patients 6,7 and 8, spontaneous episodes of more sus- 
tained ventricular tachycardia developed despite con- 
tinued reduction of VPC frequency. In Patients 6 and 
7 ventricular tachycardia also occurred during treadmill 
exercise. Most recent levels in the 4 patients in whom 
tachyarrhythmias developed were in excess of 1,000 
ng/ml (mean 1,300). 
Side effects were minor. Symptoms occurred early in 
the course of treatment and did not progress during 
follow-up. Seven patients complained of intermittent 
visual blurring and 2 noted a metallic taste. No hema- 
tologic or blood biochemistry abnormalities were ob- 
served. Electrocardiographic changes, including mod- 
erate increases in PR and QRS intervals of 10 to 20%, 
remained stable. 
In summary, flecainide has remained highly effective 
in reducing VPC frequency in these patients for as long 
as 37 months (median 25) and is symptomatically well 
tolerated.25 However, spontaneous ventricular tachy- 
cardia may still occur in some patients. Disease pro- 
gression or high plasma levels may have contributed to 
these failures. Exercise testing was useful in assessing 
proarrhythmic potential. 
Granrud, et alz6 reported preliminary results of 
long-term follow-up in 27 patients treated with fle- 
cainide. Treatment was stopped in 4 patients, because 
of sudden death in 1, heart failure in 1, right bundle 
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TABLE VI Dosage Recommendations for Oral Flecainide 
Therapy 
Usual dosage: 200-400 mg/day 
initial dose: 200 mg 
Initial maintenance dose: 100 mg every 12 hours 
Dose increments: 50 mg every 12 hours, every 4 days as needed 
Usual effective regimens: 
100, 150, and 200 mg every 12 hours 
Alternative: 100 mg every 8 hours 
Maximum dosage: 300 mg every 12 hours (600 mg/day) 
Conditions of altered dosage: 
1. End-stage renal disease (creatinine clearance 120 ml/min/ 
m2) 
2. Advanced ventricular dysfunction, heart failure and unstable 
rhythms 
3. Recommend: Schedule hospital administration: begin 100 mg 
every 12 hours: increments L every 4 to 7 days, maximum 
200 mg every 12 hours; follow plasma levels if possible. 
branch block in 1 and inadequate efficacy in 1. Side 
effects were minor. At 18 to 20 months, mean percent 
suppression of VPCs and ventricular pairs was 88% and 
suppression of ventricular tachycardia 83% (23 pa- 
tients). The average dose of flecainide was reduced to 
a mean of 320 mglday during chronic therapy, resulting 
in an average plasma drug level of 577 ng/ml. Flecainide 
was well tolerated. 
Drug Dosage 
Dosing recommendations (Table VI): Most studies 
with flecainide have used an average starting dose of 200 
mg every 12 hours, and this dose has been effective and 
well tolerated in most patients. Because of the long 
half-life of flecainide, it is likely that even smaller doses 
(100 to 150 mg every 12 hours) will provide antiar- 
rhythmic efficacy in many patients. Therefore, it is 
recommended that after a loading dose (200 mg), ther- 
apy be initiated at 100 mg every 12 hours. This dose may 
be increased in increments of 50 mg twice daily every 
4 days until efficacy has been achieved or until 400 
mg/day (200 mg twice daily) has been reached. A few 
TABLE VII Adverse Reaction Profile 
Neurocirculatory: 
Common: Dizziness, blurred vision (~30%) 
Comment: Usually minor; may decrease with time; usually 
responds to dosage reduction if needed 
Occasional: Headache and nausea (5 to 10 % ); asymptomatic lo 
atrioventricular block 
Uncommon: Flushing, chest pain, anxiety, tremor, palpitation, 
altered taste, paresthesia, fatigue, asthenia and 
hypertension 
Proarrhythmic: 
Increased VPCs: <5 to 10% of patients 
Comment: More common at subtherapeutic dosage; if so, may 
decrease with therapeutic dosage 
Facilitation of VT: (1) on ambulatory monitoring (may be independent 
of total VPC response), (2) at electrophysiologic induction, and 
(3) exercise-induced spontaneous. 
Incessant VT or VF (difficult to resuscitate): Very rare. 
Comment: Associated with high plasma drug levels (>l,OOO 
ng/ml), poor ventricular function (ejection fraction <30%), 
history of malignant arrhythmias and f concurrent antiar- 
rhythmic use; avoid, by careful patient selection and dosage 
increments, careful monitorina 
VF = ventricular fibrillation; VPC = ventricular premature complexes; 
VT = ventricular tachycardia. 
patients have required higher doses, but a dose of 600 
mglday should not be exceeded. 
Dosage increases greater than 400 mglday should not 
be made in patients at higher risk for toxicity (heart 
failure, renal failure with creatinine clearance 120 
ml/min/m2, the very elderly and weight less than 50 kg) 
unless guided by plasma drug concentrations. Again, 
initial dosage should not exceed 100 mg every 12 hours 
and increments should be made cautiously, at 4- to 
7-day intervals, allowing for steady-state plasma levels 
to be reached. Studies to determine the effect of hepatic 
impairment on flecainide elimination have not been 
completed. 
Some patients may be intolerant to or not adequately 
controlled by a dose given every 12 hours. In these cases, 
the daily dose may be divided into 8-hour intervals. The 
long half-life of flecainide suggests the possibility of 
once-daily dosing in certain patients, but this possibility 
has not been studied. 
Recognizing and Dealing with 
Adverse Reactions (Table VII) 
Flecainide is well tolerated, although minor adverse 
effects may be seen. About 30% of patients receiving an 
average dose of 400 mg/day or greater have visual dis- 
turbance (blurred vision and difficulty in accommo- 
dation, particularly on lateral gaze) or dizziness 
(lightheadedness and unsteadiness).7~s~1c~1sJ5 These 
effects most often occur after dosing, during the period 
of expected drug peak. Complaints of nausea and 
headache may occur in 5 to 10% on larger doses. Infre- 
quent effects (incidence of less than 5%) include flush- 
ing, chest pain, dyspnea, nervousness, palpitation, 
tremor, paresthesia, fatigue, asthenia and metallic taste. 
These effects are minor, transient and well tolerated in 
most patients. In 1 large study,15 13% of patients dis- 
continued flecainide because of adverse effects. How- 
ever, dosages of 400 to 600 mglday were used, and 
down-titration was not allowed. Experience in chronic 
studies indicates that adverse effects may be relieved 
while efficacy is maintained by downward dose ad- 
justments.26 Intolerance should force discontinuation 
in less than 10%. Flecainide has not caused biochemical 
or hematologic abnormalities. 
Hemodynamic and rhythm effects form the other 
basis for potential adverse reactions. Worsening of heart 
failure may occur in approximately 2% of the patients. 
First-degree atrioventricular (AV) block is seen fre- 
quently, but is usually benign. QRS widening may rarely 
progress to bundle branch block, usually asymptomatic. 
Sinus bradycardia, sinus pause, sinus arrest or more 
advanced AV block is rare, but may occur with preex- 
istent conduction system disease. Proarrhythmic effects 
are discussed herein. 
Precautions: Important drug interactions with fle- 
cainide have not been apparent. There has been no ex- 
perience with co-administration of flecainide and either 
disopyramide or verapamil. There is little rationale to 
co-administer disopyramide, particularly in view of the 
negative inotropic properties of each drug. In appro- 
priate patients, co-administration of verapamil and 
flecainide may be indicated when the potential benefit 
February 27, 1984 THE AMERICAN JOURNAL OF CARDIOLOGY Volume 53 1178 
outweighs the risk (negative inotropy and decreased AV 
conduction). 
Flecainide has not been shown to be carcinogenic in 
animal studies.“7 There are no adequate and well-con- 
trolled studies in pregnancy. Therefore, the drug should 
be used in pregnancy only if benefit justifies the un- 
known risk to the fetus. Teratogenic effects were noted 
in large doses in 1, but not another, strain of rabbit. 
Effects on human labor and delivery, and excretion in 
human milk of flecainide have not been studied. Safety 
and effectiveness of flecainide have not been established 
in children younger than 18 years of age. In view of fle- 
cainide’s modest negative inotropic effects, it should be 
used cautiously in patients with a history of congestive 
heart failure. 
Contraindications: As with other class I antiar- 
rhythmic drugs, flecainide should be considered con- 
traindicated in patients with preexisting second- or 
third-degree AV block or with bifascicular or trifascic- 
ular bundle branch block unless a pacemaker is present 
that can sustain cardiac rhythm should complete AV 
block occur. Flecainide is contraindicated in the pres- 
ence of cardiogenic shock. 
Proarrhythmic effects: a clinical caution: A clear 
understanding of the potential of antiarrhythmic agents 
to produce proarrhythmic effects is essential to their 
safe and rational administratiorG$ such is also the case 
for flecainide.29 Substantial proarrhythmic effects have 
been observed with all antiarrhythmic drugs, with an 
incidence of about 5 to 15% using ambulatory electro- 
cardiographic recording28 and about 10 to 30% during 
programmed stimulation.aO There is also concern with 
class IC agents.17x1sJ1 The risk of proarrhythmic effects 
from flecainide appears to be similar: In a survey of 588 
patients, 8% (44 patients) were believed to have such 
effects. In studies in which only stable patients were 
recruited, proarrhythmic effects were noted in about 4%, 
whereas in studies in which unstable patients with ad- 
vanced disease were recruited, the percentage was 12% 
(personal communication, Riker Laboratories). Ar- 
rhythmias associated with a long QT syndrome, noted 
commonly with quinidine,s2 appear to be rare with fle- 
cainide and are associated with toxic doses.19 Proar- 
rhythmic effects may take the form of an increased 
frequency of VPC. If facilitation is mild and occurs in 
stable patients at subtherapeutic levels, a dosage in- 
crease may be considered. Otherwise, alternative ther- 
apy should be used. An increase in repetitive beats 
(pairs and runs) irrespective of effects on total VPC 
should be a stronger indication for alternative therapy. 
Inducibility of ventricular tachycardia at electrophys- 
iologic study in nonresponding patients is unpredictable 
and may be better, worse or unchanged.13 The most 
serious arrhythmogenic effects have included rare in- 
stances of unresuscitable ventricular tachycardia or 
fibrillation. A recent review among flecainide investi- 
gators pointed to a potential role of excessive drug levels 
(>l,OOO ng/ml) in patients with advanced disease (left 
ventricular ejection fraction <30%, previous infarction, 
history of sustained ventricular tachycardia or con- 
comitant treatment with other class I antiarrhythmic 
drugs). In these very ill patients with a frequent re- 
TABLE VIII Indications for Clinical Use 
Hiahlv effective:* 
-1. ‘Uniform and multiform VPC 
2. Coupled VPC 
3. Runs of VPC (nonsustained VT) 
Selectedf prophylactic efficacy: 
Sustained VT, VF (includes electrophysiologic guided therapy) 
Investigational applications: 
1. Supraventricular tachycardiasx 
A. AV nodal reentry 
B. AV bypass tract reentry (concealed or overt WPW syn- 
drome) 
2. Arrhythmias during myocardial infarction 
l May be agent of choice for chronic VPCs; little experience to date 
with acute VPCs during myocardial infarction. 
+ Younger patients without advanced ischemic heart disease or 
ventricular dysfunction may do better. 
t Little experience for atrial flutter or fibrillation. 
AV = atrioventricular; VF = ventricular fibrillation; VPC = ventricular 
premature complex; VT = ventricular tachycardia; WPW = Wolff- 
Parkinson-White syndrome. 
fractory condition, an extremely cautious approach, or 
alternative therapy, is indicated. 
Clinical Proposal for initial Drug Use 
Flecainide’s safety, unsurpassed efficacy and near- 
ideal pharmacokinetics in patients with chronic stable 
ventricular arrhythmias suggest that it will frequently 
be the drug of choice when medical treatment is indi- 
cated. Studies summarized herein indicate that fle- 
cainide will result in greater suppression of ventricular 
ectopy, including pairs and runs in these patients, than 
will the standard drugs (quinidine and disopyramide), 
and the newer lidocaine congeners (i.e., mexiletine and 
tocainide) soon due for general release in the United 
States. Convenience of dosing (twice-daily schedule) 
exceeds that of these other drugs, and adverse effects 
jeopardizing continued therapy are low. 
Proposed indictions for clinical use (Table VIII): 
Flecainide is proposed for suppression and prevention 
of uniform and multiform ventricular premature com- 
plexes, coupled ventricular premature complexes, and 
runs of ventricular tachycardia. If the tachycardia is 
nonsustained, response is followed primarily by am- 
bulatory monitoring; if sustained, therapy may also be 
directed by programmed electrical stimulation. The 
response rate of sustained VT is lower and dependent 
on patient selection; younger patients without coronary 
disease or, if they have coronary disease, with reason- 
ably well-preserved ventricular function respond most 
favorably. ls The same may be said for other antiar- 
rhythmic drugs. 23,24 Experience to date is greatest for 
chronic arrhythmias. Class I antiarrhythmics are usually 
not effective in treating arrhythmias associated with 
digitalis intoxication; therefore, flecainide is not rec- 
ommended for such cases. Although effects of the QT 
interval are less than those after quinidine, flecainide 
has not been determined to be useful in the treatment 
of arrhythmias associated with a long QT interval. Ef- 
fects of flecainide in patients with supraventricular 
arrhythmias or acute myocardial infarction have not 
been adequately studied to provide usage recommen- 
dations at this time. In patients with advanced heart 
disease, including multiple arrhythmia mechanisms, 
conduction system disease or advanced ventricular 
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dysfunction, the increased risks of flecainide’s mild 
negative inotropic effects and potential proarrhythmic 
effects should be carefully weighed against those of 
other therapeutic alternatives.:‘“-:36 
Clinical approach: Flecainide, like other antiar- 
rhythmic drugs, should be started during inhospital 
observation. Most adverse effects of drug occur within 
a few days of initial administration. In patients with 
stable arrhythmias without a history of sustained 
tachycardia, a carefully designed outpatient plan forms 
an alternative approach. Weekly outpatient visits in- 
cluding ambulatory electrocardiographic recording and 
symptom assessment may be undertaken until a suc- 
cessful regimen is obtained. Thereafter, the patient may 
be seen at monthly intervals for 3 months, and 3-month 
intervals during the first year or as otherwise indicated 
by the patient’s condition. Ambulatory electrocardio- 
graphic recordings are obtained until an effective re- 
sponse has been achieved, in the presence of recurrent 
symptoms or dose adjustment or at about 6-month in- 
tervals during at least the first 1 to 2 years. 
For patients with a history of, or who have potential 
for, malignant arrhythmias (sustained ventricular 
tachycardia, ventricular fibrillation, poor ventricular 
function and advanced age), inhospital titration (be- 
ginning with 100 mg every 12 hours) should be obliga- 
tory. Continuous inhospital ambulatory electrocar- 
diographic recording and predischarge exercise testing 
to a symptomatic end point by treadmill or bicycle er- 
gometry are performed. Patients with a history of sus- 
tained ventricular tachycardia are usually tested with 
programmed electrical stimulation, particularly if 
spontaneous arrhythmia episodes are infrequent. Blood 
level monitoring is encouraged when doses of 400 
mglday or greater are administered and for patients 
with compromised physiologic findings. 
Investigational Use (Table VIII) 
Flecainide is 1 of 4 new antiarrhythmic drugs being 
tested in the National Institutes of Health-sponsored 
Cardiac Arrhythmia Pilot Study (CAPS), which began 
in July 1983. This study in patients with complex ar- 
rhythmias in the early period after myocardial infarc- 
tion will compare the effectiveness of selected antiar- 
rhythmic drugs in suppressing complex ventricular 
arrhythmias and evaluate their safety. If the results of 
CAPS are promising, a full-scale trial is proposed to test 
the hypothesis that elimination of ventricular ar- 
rhythmias may reduce the excessive risk of sudden 
death in this patient group. On the basis of current as- 
sessment, flecainide appears to be an excellent candi- 
date drug for such an application. 
Another application of great interest includes the use 
of flecainide for treatment of reentrant supraventricular 
arrhythmias, including those associated with AV bypass 
tracts as seen in the Wolff-Parkinson-White syndrome. 
Preliminary indications suggest that flecainide is an 
excellent drug in these applications. Hellestrand et a137 
found flecainide to be effective in treating 12 of 14 cases 
of AV bypass tract reentrant tachycardia and 8 of 9 
cases of AV nodal reentrant tachycardia evaluated by 
electrophysiologic study. Flecainide may also be useful 
in other supraventricular arrhythmias, but further 
documentation will be required. There is little experi- 
ence in the prevention or treatment of atria1 fibrillation 
or flutter with flecainide. The therapeutic use of com- 
bining flecainide with other antiarrhythmic drugs or 
nondrug management (pacemakers and internal defi- 
brillators) requires exploration. 
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